NOT FOR RELEASE, PUBLICATION
OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN
AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
(Oslo, Norway, 17 October
2016) Reference is made to previous stock exchange announcements
and the prospectus (the "Prospectus") dated 30 September 2016
concerning, inter alia, the subsequent offering (the "Subsequent
Offering") of minimum 1 and maximum 13,333,334 new shares (the
"Offer Shares") in Hofseth BioCare ASA ("HBC" or the "Company",
ticker "HBC"). The subscription price in the Subsequent Offering
was NOK 1.50, equal to the subscription price in the NOK 165.4
million private placement completed on 20 September 2016.)
The subscription period for
the Subsequent Offering ended on 17 October 2016 at 16.30 CET. At
the end of the subscription period, HBC had received subscriptions
for a total of 1 027 494 Offer Shares.
Allocation of 1 027 494
Offer Shares in the Subsequent Offering was approved by the Board
of Directors on 17 October 2016. The Subsequent Offering raised
gross proceeds of approx. NOK 1.54 million.
The Board of Directors of
HBC has approved the final allocation of the shares subscribed in
the Subsequent Offering based on the allocation criteria set out in
the Prospectus. A total of 1 000 494 Offer Shares have been
allocated to subscribers on the basis of exercised subscription
rights. 27 000 Offer Shares have been allocated to subscribers
without subscription rights.
Payment for the Offer Shares
allocated to a subscriber falls due on 24 October 2016.
Letters of allocation will
be distributed to investors giving notification of allocated new
shares and the corresponding amount to be paid by each
subscriber.
For further information,
please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth
BioCare:
Hofseth BioCare is a Norwegian biotech company that offers
high-value ingredients and finished products for humans and pets.
The company is founded on the core values of sustainability,
traceability and optimal utilization of natural resources. Through
an innovative hydrolysis technology, HBC is able to preserve the
quality of salmon oil, proteins and calcium, prepared of fresh
salmon off-cuts. HBC's objective is to contribute to the efficient
use of marine resources and deliver quality products for
ingredients and finished consumer products in the nutrition
market.
Hofseth BioCare's
headquarters are located in Ålesund, Norway with branches in Oslo,
Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange
Axess list with ticker "HBC". More information about Hofseth
BioCare at www.hofsethbiocare.com and
www.facebook.com/hofsethbiocare.
This information is subject
of the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.